Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This phase 3 trial tests whether adding the experimental drug SHR-A1912 to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma. About 280 adults whose cancer came back after at least one prior treatment will be randomly assigned …

This study tests a combination of two investigational drugs, SHR-A2102 and adebrelimab, with or without other anti-cancer therapies, in people whose head and neck squamous cell carcinoma has returned or spread. The goal is to find safe and effective doses and see if the combinati…

This early-stage study tests a new injection called SHR-4506 in 102 adults with advanced malignant tumors who have run out of standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow the disease. Participants must …

This phase 2 trial is testing a new drug called SHR-1826 in 90 people with advanced non-small cell lung cancer that has worsened after other treatments. Participants receive the drug by IV every three weeks. The study aims to see if the drug can shrink tumors and how safe it is.

This study tests whether adding two drugs (adebrelimab and SHR-8068) to standard chemoradiation helps shrink advanced rectal cancer before surgery. About 165 adults aged 18-75 with resectable tumors will participate. The goal is to see if more patients achieve a complete response…

This study tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard two-drug combos for people with advanced liver cancer that cannot be removed by surgery. About 590 adults who have not had prior cancer treatment will participate. The …

This early-stage trial tests a new drug called SHR-2524 combined with bevacizumab in 36 people with advanced liver cancer that hasn't been treated before. The main goals are to check safety, how the body processes the drugs, and to get an early look at whether the combination mig…

This study tests a new drug called SHR-4375 combined with other anti-cancer treatments in people with advanced solid tumors that no longer respond to standard care. The trial will enroll about 198 participants to check safety, find the best dose, and see if tumors shrink. It is a…

This phase 3 trial is testing whether adding an experimental drug called SHR-A2009 to the standard targeted therapy aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 participants who have not…

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This Phase 3 trial is testing a new drug called SHR-A2102 against standard chemotherapy in 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and PD-(L)1 inhibitors. The main goal is to see if SHR-A2102 helps people live longer.…

This study tests an experimental drug called SHR-A1904 in people with advanced biliary tract cancer (bile duct cancer) that has not responded to previous treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The trial aims to see if the drug can shrin…

This study tests a new drug called SHR-9839 combined with other cancer treatments in people with advanced solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 70 adults aged 18 to 70 with measurable tumors and good perfo…

This study tests a new drug called SHR-8068 combined with other cancer treatments for people with colorectal cancer. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth. About 200 adults aged 18 to 75 will take part, and they must provide t…

This study tests a new combination of drugs (SHR-8068, adebrelimab, and others) in about 139 people with advanced kidney cancer that cannot be removed by surgery or has spread. The goal is to see if the treatment is safe and can shrink tumors. Participants will receive the drugs …

This phase 3 trial is testing whether a combination of two drugs, SHR-A2102 and adebrelimab, works better than standard chemotherapy for people with advanced bladder cancer that has not been treated before. About 462 participants will be randomly assigned to receive either the ne…

This study tests a new drug called SHR-4849 combined with other cancer medicines in people with advanced solid tumors. The goal is to see if the combination is safe and can shrink tumors. About 120 adults aged 18 to 75 with measurable tumors and good organ function will take part…

This phase 3 trial is testing whether a new combination of drugs (SHR-A1811, adebrelimab, and chemotherapy) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The study will enrol…

This study tests several combinations of a new drug called SHR-A1811 with immunotherapy and/or chemotherapy in people with advanced HER2-positive stomach or gastroesophageal junction cancer. The phase Ib part checks safety and the best dose, while phase II looks at how well the t…

This early-stage trial is testing a new drug, SHR-7782, in 200 adults with advanced malignant cancer that has not responded to standard treatments. The main goals are to find the safest dose and check for side effects, while also watching for any tumor shrinkage. Participants mus…

This study tests a new combination of drugs (SHR-8068, adebrelimab, and chemotherapy) against the current standard treatment for advanced bile duct cancer. About 604 people with inoperable cancer who haven't had prior treatment will take part. The goal is to see if the new combo …

This early-stage study tests a new drug called SHR-A1811(sc) given as a shot under the skin for people with solid tumors. The main goals are to see how the drug moves through the body, check for side effects, and get an early look at whether it helps shrink tumors. About 107 adul…

This Phase 2 study is testing several new drug combinations for people with stomach or gastroesophageal junction cancer who have not had prior treatment. The combinations include an immunotherapy drug (adebrelimab) plus targeted drugs (SHR-A1811, SHR-A1904, or SHR-8068) and chemo…

This study tests an experimental drug called SHR-1681 in 300 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and how…

This study tests a new injection called SHR-2017 in 210 adults with solid tumors that have spread to their bones. The goal is to see if it can prevent bone complications like fractures and pain, compared to an existing drug (denosumab). Participants will receive either high or lo…

This phase 3 trial is testing whether a new combination of drugs (SHR-A1811 plus SHR-1316) works better than the current standard treatment for a specific type of advanced breast cancer called PD-L1-positive triple-negative breast cancer. The study will enroll 400 women whose can…

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This early-stage study is testing a new drug called SHR-3821 in 162 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This Phase 3 trial tests whether adding a new drug (SHR-8068) to a standard immunotherapy (adebrelimab) and chemotherapy works better than the current standard (tislelizumab plus chemo) for people with advanced non-small cell lung cancer. About 460 participants will be randomly a…

This study tests a new drug called SHR-A1811 combined with standard chemotherapy (carboplatin and bevacizumab) in 150 women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to find the safest dose and see if the combination shrinks tumors …

This early-stage study tests whether a single dose of the experimental drug SHR-1894 is safe and how it moves through the body. It involves 40 healthy adults aged 18 to 45. No treatment is given; the goal is to gather safety information before testing in patients with dermatitis.